A Phase 1b, Double-Blind, Randomized, Placebo Controlled, Multiple Ascending Dose Study of the Safety, Tolerability and Immune Effects of the Intranasal Anti-CD3 Monoclonal Antibody Foralumab in Primary and Secondary Progressive MS
Latest Information Update: 30 Dec 2022
Price :
$35 *
At a glance
- Drugs Foralumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Tiziana Life Sciences
- 29 Dec 2022 According to a Tiziana Life Sciences media release, Dr. Tanuja Chitnis, MD, Professor of Neurology is the principle investigator in the trial.
- 29 Dec 2022 According to a Tiziana Life Sciences media release, data from a Secondary Progressive Multiple Sclerosis patient treated with intranasal treatment with foralumab were presented on June 2, 2022 at the consortium of multiple sclerosis centers (CMSC) 2022 annual meeting.
- 14 Feb 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.